<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927065</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1273-P205</org_study_id>
    <nct_id>NCT04927065</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants</brief_title>
  <official_title>A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211,&#xD;
      mRNA-1273, mRNA-1273.617.2, and mRNA-1273.213.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study will consist of 5 parts: A, B, C, D, and E.&#xD;
&#xD;
      Part A will evaluate 2 dose levels of the mRNA-1273.211 vaccine when administered as a single&#xD;
      booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have&#xD;
      previously received 2 doses of mRNA-1273.&#xD;
&#xD;
      Part B will evaluate the mRNA-1273 vaccine when administered as a single booster dose to&#xD;
      adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously&#xD;
      received 2 doses of mRNA-1273.&#xD;
&#xD;
      Part C will evaluate 2 dose levels of the mRNA-1273.617.2 vaccine when administered as a&#xD;
      single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study&#xD;
      who have previously received 2 doses of mRNA-1273.&#xD;
&#xD;
      Part D will evaluate 2 dose levels of the mRNA-1273.213 vaccine when administered as a single&#xD;
      booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have&#xD;
      previously received 2 doses of mRNA-1273.&#xD;
&#xD;
      Part E will be enrolled at a single clinical study site. Part E will evaluate the&#xD;
      mRNA-1273.213 vaccine when administered as a single booster dose to adult participants who&#xD;
      have previously received 2 doses of any SARS-CoV-2 mRNA authorized vaccine, including&#xD;
      mRNA-1273.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 16, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroresponse Rate of Vaccine Recipients</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)</measure>
    <time_frame>Up to Day 8 (7 days post-vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Up to Day 29 (28 days post-vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs)</measure>
    <time_frame>Up to Day 366</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT of SARS-CoV-2-Specific Antibody</measure>
    <time_frame>Days 1, 15, 181, and 366</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroresponse Rate of Vaccine Recipients</measure>
    <time_frame>Days 1, 15, 181, and 366</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">3620</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Part A: mRNA-1273.211 50 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.211 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: mRNA-1273.211 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.211 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: mRNA-1273 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: mRNA-1273.617.2 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.617.2 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: mRNA-1273.617.2 50 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.617.2 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: mRNA-1273.213 50 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.213 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: mRNA-1273.213 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: mRNA-1273.213 100 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1273.211</intervention_name>
    <description>Sterile liquid for injection</description>
    <arm_group_label>Part A: mRNA-1273.211 100 μg</arm_group_label>
    <arm_group_label>Part A: mRNA-1273.211 50 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1273</intervention_name>
    <description>Sterile liquid for injection</description>
    <arm_group_label>Part B: mRNA-1273 100 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1273.617.2</intervention_name>
    <description>Sterile liquid for injection</description>
    <arm_group_label>Part C: mRNA-1273.617.2 100 μg</arm_group_label>
    <arm_group_label>Part C: mRNA-1273.617.2 50 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1273.213</intervention_name>
    <description>Sterile liquid for injection</description>
    <arm_group_label>Part D: mRNA-1273.213 100 μg</arm_group_label>
    <arm_group_label>Part D: mRNA-1273.213 50 μg</arm_group_label>
    <arm_group_label>Part E: mRNA-1273.213 100 μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  For female participants of childbearing potential: negative pregnancy test, adequate&#xD;
             contraception or has abstained from all activities that could result in pregnancy for&#xD;
             at least 28 days prior to Day 1, agreement to continue adequate contraception or&#xD;
             abstinence through 3 months following the vaccination, and not currently&#xD;
             breastfeeding.&#xD;
&#xD;
          -  In Parts C and D, study participants must have been either previously enrolled in the&#xD;
             mRNA-1273-P301 (COVE) study, must have received 2 doses of mRNA-1273 in that study,&#xD;
             with their second dose at least 6 months prior to enrollment in this study&#xD;
             (mRNA-1273-P205), and must be currently enrolled and compliant in that study (that is,&#xD;
             has not withdrawn or discontinued early); or participant must have received 2 doses of&#xD;
             mRNA-1273 under the Emergency Use Authorization (EUA) with their second dose at least&#xD;
             6 months prior to enrollment in mRNA-1273-P205, and able to provide proof of&#xD;
             vaccination status at the time of screening (Day 1). In Part E, study participants&#xD;
             must have previously received an mRNA vaccine for the prevention of COVID-19 in&#xD;
             another clinical study or under EUA with their second dose at least 6 months prior to&#xD;
             enrollment in mRNA-1273-P205 and must be able to provide proof of vaccination status&#xD;
             at the time of screening (Day 1).&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 14&#xD;
             days, as defined by the US Centers for Disease Control and Prevention (CDC) as a close&#xD;
             contact of someone who has had COVID-19.&#xD;
&#xD;
          -  Known history of SARS-CoV-2 infection including during the mRNA 1273-P301 (COVE) study&#xD;
             or within the last 18 months.&#xD;
&#xD;
          -  Is acutely ill or febrile (temperature ≥38.0°Celsius/[100.4°Fahrenheit]) less than 72&#xD;
             hours prior to or at the Screening Visit (Day 0) or Day 1.&#xD;
&#xD;
          -  Has a medical, psychiatric, or occupational condition that may pose additional risk as&#xD;
             a result of participation, or that could interfere with safety assessments or&#xD;
             interpretation of results according to the investigator's judgment.&#xD;
&#xD;
          -  Has received systemic immunosuppressants or immune-modifying drugs for &gt;14 days in&#xD;
             total within 6 months prior to Screening (for corticosteroids ≥10 milligrams (mg)/day&#xD;
             of prednisone equivalent) or is anticipating the need for immunosuppressive treatment&#xD;
             at any time during participation in the study.&#xD;
&#xD;
          -  Known or suspected allergy or history of anaphylaxis, urticaria, or other significant&#xD;
             AR to the vaccine or its excipients.&#xD;
&#xD;
          -  Has a medical history consistent with a protocol-specified AESI.&#xD;
&#xD;
          -  Has received or plans to receive any licensed vaccine ≤28 days prior to the injection&#xD;
             (Day 1) or a licensed vaccine within 28 days before or after they study injection,&#xD;
             with the exception of influenza vaccines, which may be given 14 days before or after&#xD;
             receipt of a study vaccine.&#xD;
&#xD;
          -  Has received systemic immunoglobulins or blood products within 3 months prior to the&#xD;
             Screening Visit (Day 0) or plans for receipt during the study.&#xD;
&#xD;
          -  Has donated ≥450 milliliters (mL) of blood products within 28 days prior to the&#xD;
             Screening Visit (Day 0) or plans to donate blood products during the study.&#xD;
&#xD;
          -  Is currently experiencing an SAE in Study mRNA-1273-P301 (COVE) at the time of&#xD;
             screening for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>877-913-3286</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Benchmark Research (California)</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95864</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center For Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research-(Savannah Georgia)</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research (Iowa)</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johnson County Clinical Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research-(Baton Rouge, Louisiana)</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research-(Rockville Maryland)</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington State University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research (Grand Island, Nebraska)</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research (Norfolk-Nebraska)</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research-(Omaha Nebraska)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial Management Associates</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Benchmark Research - Austin - HyperCore</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Benchmark Research - Fort Worth - HyperCore</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA-1273</keyword>
  <keyword>mRNA-1273 vaccine</keyword>
  <keyword>mRNA-1273.211</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>SARS-CoV-2 Vaccine</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Messenger RNA</keyword>
  <keyword>COVID 19</keyword>
  <keyword>COVID 19 Vaccine</keyword>
  <keyword>Moderna</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

